Humoral response and safety of the <scp>BNT162b2</scp> and <scp>mRNA</scp>‐1273 <scp>COVID</scp>‐19 vaccines in patients with haematological diseases treated with <scp>anti‐CD20</scp> antibodies: An observational study

Nishikubo, Masashi; Shimomura, Yoshimitsu; Maruoka, Hayato; Nasu, Seiko; Nishioka, Tomomi; Sakizono, Kenji; Mitsuyuki, Satoshi; Kubo, Tomoyo; Okada, Naoki; Nakagawa, Daishi; Kamijo, Kimimori; Imoto, Hiroharu; Yamamoto, Ryusuke; Nagai, Yuya; Hiramoto, Nobuhiro; Yoshioka, Satoshi; Yonetani, Noboru; Matsushita, Akiko; Miyakoshi, Chisato; Doi, Asako; Ishikawa, Takayuki

doi:10.1111/bjh.18151

Cited by 6 publications

(2 citation statements)

References 10 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study serves as an extension of our previous research (Figure S1). In our previous investigation, we examined the humoral and cellular responses to a third vaccination in patients with haematological diseases who received their last dose of anti‐CD20 antibodies within 12 months before their first two vaccine doses 7 . Patients were recruited between July and November 2022.…”

Section: Methodsmentioning

confidence: 99%

“…In our previous investigation, we examined the humoral and cellular responses to a third vaccination in patients with haematological diseases who received their last dose of anti-CD20 antibodies within 12 months before their first two vaccine doses. 7 Patients were recruited between July and November 2022. When information regarding participants' humoral responses after the two vaccine doses was available, as in our other previous study, 8 we analysed the available data to evaluate their immune responses sequentially.…”

Section: Study Design and Participantsmentioning

confidence: 99%

See 1 more Smart Citation

Sequential cellular and humoral responses after repetitive COVID‐19 vaccination in patients treated with anti‐CD20 antibodies

Nishikubo,

Shimomura,

Yamamoto

et al. 2023

Br J Haematol

Self Cite

View full text Add to dashboard Cite

SummaryPatients treated with anti‐CD20 antibodies for haematological disorders have insufficient immune responses to mRNA COVID‐19 vaccines; however, relevant sequential data are lacking. We sequentially evaluated the humoral and cellular immune responses in 22 patients who had received anti‐CD20 antibodies within 12 months before the first vaccination, before and after the third and fourth vaccinations. Humoral responses improved gradually, along with the resolution of B‐cell depletion. A steady increase was noted in cellular responses, regardless of the B‐cell status. Our findings suggest the potential benefit of repeated vaccinations in these patients until B‐cell recovery is confirmed while enhancing cellular responses.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Study Design and Participantsmentioning

confidence: 99%